Clinical trials: Adebrelimab (SHR-1316)
Urothelial Carcinoma, Advanced Urothelial Carcinoma
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)
This is a multicenter, open-label, Phase II clinical trial to evaluate the efficacy and safety of Trastuzumab Rezetecan (SHR-A1811) or in combination with Adebrelimab (SHR-1316) for HER2-expressing locally advanced or metastatic…
- Conditions
- Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent
- Trial name
- TRAIN-UC-01 (NCT07241793)
- Testing
- Adebrelimab, Trastuzumab Rezetecan
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sun Yat-sen University
Muscular Invasive Bladder Cancer (MIBC)
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of…
- Trial name
- NCT06879145
- Testing
- SHR-A2102；Adebrelimab
- Where
- China
- Volunteers
- 840 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Locally Advanced Gastric or Gastroesophageal Junction Cancer
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
This study was a randomized, double-blind, multi-center phase III clinical trial to evaluate the event-free survival (EFS) of Adebrelimab with S-1 and oxaliplatin versus placebo combined with S-1 and oxaliplatin, and to evaluate…
- Trial name
- NCT07522151
- Testing
- Adebrelimab plus S-1 and oxaliplatin, Adebrelimab blank preparation plus S-1 and oxaliplatin.
- Where
- China
- Volunteers
- 874 people
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
Adebrelimab (SHR-1316), XELOX
A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
To observe and evaluate the efficacy and safety of adebrelimab combination chemotherapy regimen in the perioperative treatment of surgically resectable gastric cancer/adenocarcinoma of the gastroesophageal junction.
- Conditions
- Adebrelimab (SHR-1316), XELOX, GC/GEJC
- Trial name
- NCT06506292
- Testing
- Adebrelimab, XELOX
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Limited-stage Small-cell Lung Cancer
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung…
- Trial name
- NCT07798947
- Testing
- SHR-7787 Injection, SHR-1316
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Adebrelimab (SHR-1316), Decitabine
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer
Pancreatic cancer is a kind of digestive system tumor with extremely high malignancy and poor prognosis. Although the trend of benefit from immunotherapy in combination with chemotherapy is currently reflected in several…
- Conditions
- Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer
- Trial name
- NCT06454448
- Testing
- Adebrelimab;decitabine;
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Triple Negative Breast Cancer
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer
It is a randomized, open label, positive drug controlled, multicenter design Phase III clinical trial, aims to compare the efficacy and safety of SHR-A1811 combined with Adebrelimab and the treatment selected by the researchers…
- Trial name
- NCT07679360
- Testing
- Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-squamous Non-small Cell Lung Cancer
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations
- Trial name
- NCT06335355
- Testing
- Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin, Camrelizumab + Pemetrexed + Carboplatin, Adebrelimab + Pemetrexed + Carboplatin
- Where
- China
- Volunteers
- 401 people
- Sponsor
- Shanghai Shengdi Pharmaceutical Co., Ltd
Cholangiocarcinoma Cancer, Adebrelimab (SHR-1316)
Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE
Biliary tract malignancies (BTC) are malignant tumors that originate from the epithelium of the bile ducts. Currently, the optimal treatment for biliary tract malignancies is radical surgical resection.
- Trial name
- ACHIEVE (NCT06607276)
- Testing
- Adebrelimab and capecitabine, capecitabine
- Where
- 4 sites in China
- Volunteers
- 122 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Adebrelimab (SHR-1316), Bevacizumab
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
his is a single-arm, phase II clinical study evaluating the efficacy and safety of low-dose bevacizumab (7.5 mg/kg, Q3W) plus adebrelimab (1200 mg, Q3W) combined with transarterial chemoembolization (TACE) followed by hepatic…
- Conditions
- Adebrelimab (SHR-1316), Bevacizumab, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07543783
- Testing
- Transarterial Chemoembolization (TACE), Hepatic Arterial Infusion Chemotherapy (HAIC, FOLFOX), Adebrelimab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Esophageal Cancer, ESCC
An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging
This study will evaluate whether two positron emission tomography/computed tomography (PET/CT) scans performed before treatment-68Ga-FAPI and 18F-FDG-can help predict how well patients with resectable, locally advanced thoracic…
- Trial name
- NCT07770672
- Testing
- Retlirafusp Alfa Plus Chemotherapy, Adebrelimab Plus Chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Tan Lijie
Limited Stage Small Cell Lung Cancer
The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer
To compare the efficiency between surgery and radiotherapy after SHR-1316 (Adebrelimab)and platinum-containing doublet induction therapy for limited-stage small cell lung cancer
- Trial name
- NCT05496166
- Testing
- chemotherapy and SHR-1316(Adebrelimab) comnined with surgery or radiotherapy
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Esophageal Cancer (EsC)
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
This study is a prospective, observational clinical study. In this study, 30 patients with resectable locally advanced esophageal squamous carcinoma will be prospectively enrolled and treated with adebrelimab (SHR-1316) combined…
- Trial name
- NCT06869213
- Testing
- Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Adebrelimab (SHR-1316), NSCLC
Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
This study is a single arm, prospective, multicenter clinical trial, and eligible patients will receive the following treatment regimen: Adebrelimab combined with chemotherapy.The study includes a screening period (from the…
- Conditions
- Adebrelimab (SHR-1316), NSCLC, Chemotherapy
- Trial name
- NCT07035392
- Testing
- Adebrelimab, chemotherapy
- Volunteers
- 32 people
- Sponsor
- Zhangzhou Municipal Hospital